Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNIC ACID versus TORSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNIC ACID versus TORSEMIDE.
ETHACRYNIC ACID vs TORSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Torsemide inhibits the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption, leading to increased urine output and decreased extracellular fluid volume.
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
Oral or intravenous: 5-20 mg once daily; may titrate up to 40 mg daily. Usual maintenance: 5-10 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 4-8 hours in cirrhosis and with advanced age. In renal failure (CrCl <30 mL/min), half-life may exceed 8 hours.
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Approximately 80% renal (20% unchanged, 60% as metabolites, mainly glucuronide conjugate), 20% biliary/fecal. In renal impairment, clearance is reduced and half-life prolonged.
Category C
Category A/B
Loop Diuretic
Loop Diuretic